Company Seeks License to Import Government-Grade THC
Published Date: 6/17/2026
Notice
Summary
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Application to Import Schedule I Drugs
On May 7, 2026, AndersonBrecon, Inc. DBA PCI Pharma Services applied to be registered to import three Schedule I controlled substances: tetrahydrocannabinols (drug code 7370), 3,4-methylenedioxymethamphetamine (drug code 7405), and dimethyltryptamine (drug code 7435). The company states it plans to import those listed substances for clinical trials, and any import authorization would be limited to the listed drug codes.
No Authorization for Commercial Finished Dosage Imports
The notice explicitly states that any authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Approval of a registration will be limited to activities consistent with 21 U.S.C. 952(a)(2).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-19400, Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I
The Drug Enforcement Administration wants to put five specific hallucinogenic drugs into Schedule I, meaning they’ll be treated as illegal with strict rules. This affects anyone who makes, sells, studies, or owns these drugs, adding serious legal consequences. You have until October 23, 2026, to share your thoughts or ask for a hearing before the rule might become official.
2026-19232, Esther Villanueva Valdes, M.D.; Decision and Order
Dr. Esther Villanueva Valdes from Puerto Rico lost her DEA registration because she’s no longer allowed to handle controlled substances and was excluded from federal health programs like Medicare and Medicaid. She didn’t ask for a hearing, so the decision to revoke her registration is final. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
2026-19231, Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
Starting October 21, 2026, diphenidine and its related forms will be officially listed as Schedule I drugs, meaning they’re considered highly controlled with no accepted medical use. This change affects anyone who makes, sells, studies, or even possesses diphenidine, bringing strict rules and serious penalties. The move helps the U.S. follow international drug laws and keep communities safer.
2026-18604, Joseph John Stubbers III, D.O.; Decision and Order
Dr. Joseph John Stubbers III from Ohio lost his DEA registration to handle controlled substances because he no longer has the legal authority to prescribe them in Ohio. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration as of February 28, 2026. This means he can’t legally prescribe or manage controlled drugs anymore, impacting his medical practice and patients.
Previous / Next Documents
Previous: 2026-12142, Importer of Controlled Substances Application: Aphena Pharma Solutions MD, LLC
Aphena Pharma Solutions MD, LLC wants to become an official importer of methamphetamine, a controlled substance. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how methamphetamine is imported and tracked, with no immediate cost changes announced.
Next: 2026-12144, Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.